The case study "Biopure Corporation" by John Gourville is a popular marketing and business

strategy case taught at many B-schools. Here's an easy-to-understand, detailed explanation of what's
included:

🎯 Basic Background:

Biopure Corporation is a biotech company that developed two blood substitute products:

1. Hemopure – for human use

2. Oxyglobin – for veterinary use (dogs)

These are oxygen-carrying blood substitutes that don’t need to be refrigerated and are universally
compatible — unlike real blood, which must match blood types and has storage issues.

🧪 Technology/Innovation:

 Hemopure and Oxyglobin are based on hemoglobin-based oxygen carriers (HBOCs).

 They help carry oxygen in emergencies, especially where blood isn’t available or feasible
(like rural areas, ambulances, battlefield, etc.).

🏢 Company Dilemma:

Biopure has a big decision to make:

 Should they launch Oxyglobin (veterinary product) now, before Hemopure (human
product) gets FDA approval?

 Or wait until both can be launched around the same time?

💭 Key Strategic Concerns:

1. Cannibalization risk: If they launch Oxyglobin early at a low price, doctors and investors
might undervalue Hemopure.

2. Market perception: Will launching a dog blood substitute make Hemopure look less
“premium” or serious?

3. First-mover advantage: Oxyglobin is ready to launch now, and there’s no competition in the
pet market. Should they take the opportunity?

📊 Market Information:

 Veterinary market: Untapped and price-sensitive. Vets are not used to offering blood
substitutes but might love a stable, easy-to-store option like Oxyglobin.
  Human market: Large but heavily regulated. Approval and adoption take time and are high-
risk and high-reward.

💵 Financial Angle:

 The company is burning cash and needs revenue.

 Oxyglobin can generate short-term revenue and help support further development and
marketing for Hemopure.

📌 Core Business Questions Discussed in the Case:

1. Should Biopure launch Oxyglobin now or wait?

2. How do they position and price Oxyglobin and Hemopure?

3. How do they manage customer perception across two very different markets (human vs
veterinary)?

4. What’s the best go-to-market strategy for each product?

5. What are the risks of delaying the launch of Oxyglobin?

💡 Key Learnings:

 Product portfolio strategy: How to manage two related products in different markets.

 Positioning and pricing: How pricing one product affects the perception of another.

 Marketing dilemma: When and how to enter a new market.

 Cross-market implications: Veterinary vs Human healthcare markets.

 Risk vs reward: Balancing quick revenue with long-term brand/image building.

🧠 Summary in Easy Words:

Biopure made two amazing blood substitutes—one for dogs, one for humans. The dog version
(Oxyglobin) is ready to sell right away, but the human one (Hemopure) still needs government
approval. The company is confused: Should they sell the dog product now and make money, or wait
and launch both together so the human one doesn’t look “less special”? The case dives into
marketing, pricing, risk, and business strategy to help students think through the decision.
Great! Let’s break down how the concepts of Go-To-Market (GTM) Strategy, Segmentation,
Targeting, and Positioning (STP) are used in the Biopure Corporation case in easy words:

💼 1. Go-To-Market (GTM) Strategy:

Definition (Easy words):

A GTM strategy is how a company plans to sell and promote a product to customers. It includes
when, where, and how to launch, and who to sell to.

In the Biopure case:

Biopure has two separate GTM strategies to consider:

 For Oxyglobin (Dog Product):

o They can launch immediately, as it’s FDA-approved for veterinary use.

o They would target veterinarians, animal hospitals, and pet owners.

o Selling would be through veterinary clinics or distribution partners.

o Pricing needs to be affordable, since the vet market is price-sensitive.

 For Hemopure (Human Product):

o Can’t launch until FDA approval (might take time).

o GTM would involve emergency services, hospitals, military, and rural clinics.

o Would need education, partnerships, and demos to doctors.

o Must show life-saving value, especially in areas with blood shortages.

🧩 2. Segmentation:

Definition (Easy words):

Segmentation means dividing the overall market into smaller groups based on their needs,
behaviors, or characteristics.

In the Biopure case:

Biopure divides its market into:

 Veterinary Market (for Oxyglobin):

o Segments: Emergency vet care, specialty clinics, pet owners who value premium
care.

 Human Market (for Hemopure):

o Segments: Hospitals in urban areas, ambulances, rural health centers,

military/defense, and disaster relief organizations.

Each segment has different needs—some want quick emergency solutions, others want long-term
storage or universal compatibility.
🎯 3. Targeting:

Definition (Easy words):

Targeting means choosing which segments to focus on first, based on who is most likely to buy.

In the Biopure case:

 Oxyglobin (Vet Market):

o Target: Veterinarians in emergency clinics or high-end pet hospitals.

o These are places where dog surgeries or emergencies need quick oxygen solutions.

o Also target early adopters in the veterinary community who are open to innovation.

 Hemopure (Human Market):

o Target: Hospitals in areas with blood shortages, military, and disaster zones.

o These groups need reliable blood alternatives and are more likely to take the risk of
trying a new solution.

🧠 4. Positioning:

Definition (Easy words):

Positioning is about how you want customers to see your product compared to others. It’s about the
image, value, and benefits you want to highlight.

In the Biopure case:

 Oxyglobin Positioning:

o Positioned as a reliable, safe, and easy-to-use oxygen-carrying product for dogs.

o Message: “Give your pets the best care—instant oxygen support during
emergencies.”

o Challenge: Not make it look “too cheap”, so it doesn't affect the premium image of
Hemopure.

 Hemopure Positioning:

o Positioned as a life-saving, high-tech, innovative blood substitute for humans.

o Message: “Reliable oxygen when blood isn’t available. No blood type, no

refrigeration—just save lives.”

o Needs to look high-value and premium, especially since it’ll be compared with real
blood.

🌟 Summary Table (for quick memory):

Concept Oxyglobin (Vet) Hemopure (Human)

Launch now, use vet clinics, low-cost

GTM Strategy Wait for approval, target hospitals/military
model

Segmentation Pet emergency care, specialty clinics Urban/rural hospitals, ambulances, military

Targeting Vets in high-end clinics, early adopters Military, disaster zones, rural hospitals

Safe, quick oxygen for pets; easy & Life-saving, advanced tech; reliable in any
Positioning
affordable situation